Biotechnology company Advanced Cell Technology (ACT) has lost its chief executive, Gary Rabin, who resigned on 22 January. The firm, based in Marlborough, Massachusetts, faces the possibility of bankruptcy after a series of financial missteps. ACT is running the only trials approved by the US Food and Drug Administration to test therapies involving embryonic stem cells.
展开▼
